Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
56.1M
-
Shares change
-
+20.1M
-
Total reported value, excl. options
-
$219M
-
Value change
-
+$80.4M
-
Put/Call ratio
-
1
-
Number of buys
-
62
-
Number of sells
-
-32
-
Price
-
$3.91
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q4 2017
120 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q4 2017.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.1M shares
of 123M outstanding shares and own 45.51% of the company stock.
Largest 10 shareholders include Broadfin Capital, LLC (7.1M shares), BAKER BROS. ADVISORS LP (5.85M shares), Consonance Capital Management LP (4.47M shares), BlackRock Inc. (4.02M shares), venBio Select Advisor LLC (3.89M shares), GREAT POINT PARTNERS LLC (3.82M shares), Vanguard Group Inc (3.64M shares), MILLENNIUM MANAGEMENT LLC (2.07M shares), JPMORGAN CHASE & CO (1.43M shares), and EMERALD ADVISERS INC/PA (1.37M shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.